Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.e514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Zhou D, Wang L, Zhu L, Ye X. MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072840.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin Y, Qiu T, Xie Z, Chen X, Liu P, Yang J, et al. MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2023;149(11):8483–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.

CAS  PubMed  Google Scholar 

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017;129(20):2760–70.

Article  CAS  PubMed  Google Scholar 

Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi ZY, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):145.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.

Article  PubMed  PubMed Central  Google Scholar 

Fernandez-Rodriguez C, Bellosillo B, Garcia-Garcia M, Sanchez-Gonzalez B, Gimeno E, Vela MC, et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;28(10):2104–6.

Article  CAS  PubMed  Google Scholar 

Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105(2):424–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res. 2016;22(11):2755–64.

Article  CAS  PubMed  Google Scholar 

Lee JH, Jeong H, Choi JW, Oh H, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep. 2017;7(1):1785.

Article  PubMed  PubMed Central  Google Scholar 

Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. 2017;23(9):2232–44.

Article  CAS  PubMed  Google Scholar 

Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3(9): e139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Challa-Malladi M, Lieu Yen K, Califano O, Holmes AB, Bhagat G, Murty Vundavalli V, et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20(6):728–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guégan JP, Ginestier C, Charafe-Jauffret E, Ducret T, Quignard JF, Vacher P, et al. CD95/Fas and metastatic disease: what does not kill you makes you stronger. Semin Cancer Biol. 2020;60:121–31.

Article  PubMed  Google Scholar 

Zhou J, Zuo M, Li L, Li F, Ke P, Zhou Y, et al. PIM1 and CD79B mutation status impacts the outcome of primary diffuse large B-cell lymphoma of the CNS. Front Oncol. 2022;12: 824632.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs. 2012;21(4):425–36.

Article  CAS  PubMed  Google Scholar 

Szydłowski M, Garbicz F, Jabłońska E, Górniak P, Komar D, Pyrzyńska B, et al. Inhibition of PIM kinases in DLBCL targets MYC transcriptional program and augments the efficacy of anti-CD20 antibodies. Cancer Res. 2021;81(23):6029–43.

Article  PubMed  Google Scholar 

Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021;35(2):522–33.

Article  CAS  PubMed  Google Scholar 

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131–44.

Article  PubMed  Google Scholar 

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204.

Article  PubMed  PubMed Central  Google Scholar 

Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–70.

Article  CAS  PubMed  Google Scholar 

Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci. 2021;22(7):3765.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. Front Immunol. 2017;8:1178.

Article  PubMed  PubMed Central  Google Scholar 

Kumar A, Suryadevara N, Hill TM, Bezbradica JS, Van Kaer L, Joyce S. Natural killer T cells: an ecological evolutionary developmental biology perspective. Front Immunol. 1858;2017:8.

Google Scholar 

Krijgsman D, Hokland M, Kuppen PJK. The role of natural killer T cells in cancer-a phenotypical and functional approach. Front Immunol. 2018;9:367.

Article  PubMed  PubMed Central  Google Scholar 

Hernández SS, Jakobsen MR, Bak RO. Plasmacytoid dendritic cells as a novel cell-based cancer immunotherapy. Int J Mol Sci. 2022;23(19):11397.

Article  PubMed  PubMed Central  Google Scholar 

Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302(1):259–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mhaidly R, Mechta-Grigoriou F. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies. Semin Immunol. 2020;48: 101417.